CN110573170A - 使用脂肪来源的干细胞治疗多发性硬化症 - Google Patents

使用脂肪来源的干细胞治疗多发性硬化症 Download PDF

Info

Publication number
CN110573170A
CN110573170A CN201880028213.1A CN201880028213A CN110573170A CN 110573170 A CN110573170 A CN 110573170A CN 201880028213 A CN201880028213 A CN 201880028213A CN 110573170 A CN110573170 A CN 110573170A
Authority
CN
China
Prior art keywords
hadscs
cells
lipoaspirate
tissue
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880028213.1A
Other languages
English (en)
Chinese (zh)
Inventor
埃胡德·马罗姆
弗里达·格里恩斯潘
迪马·尤金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stem Cell Medicine Ltd
Original Assignee
Stem Cell Medicine Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Cell Medicine Ltd filed Critical Stem Cell Medicine Ltd
Publication of CN110573170A publication Critical patent/CN110573170A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880028213.1A 2017-05-15 2018-05-14 使用脂肪来源的干细胞治疗多发性硬化症 Pending CN110573170A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506006P 2017-05-15 2017-05-15
US62/506,006 2017-05-15
PCT/IL2018/050523 WO2018211498A1 (en) 2017-05-15 2018-05-14 Treatment of multiple sclerosis with adipose-derived stem cells

Publications (1)

Publication Number Publication Date
CN110573170A true CN110573170A (zh) 2019-12-13

Family

ID=64274150

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880028213.1A Pending CN110573170A (zh) 2017-05-15 2018-05-14 使用脂肪来源的干细胞治疗多发性硬化症

Country Status (8)

Country Link
US (1) US11510946B2 (https=)
EP (1) EP3624816A4 (https=)
JP (1) JP2020519645A (https=)
CN (1) CN110573170A (https=)
AU (1) AU2018270396B2 (https=)
CA (1) CA3062123A1 (https=)
IL (1) IL269893B2 (https=)
WO (1) WO2018211498A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115461447A (zh) * 2020-01-20 2022-12-09 干细胞医药有限公司 含有来自于脂肪源性干细胞的调制培养基的蛋白质浓缩物的美容组合物
CN115624570A (zh) * 2022-12-21 2023-01-20 北京瑷格干细胞科技有限公司 人脂肪间充质干细胞在制备治疗结缔组织疾病药物中的应用
CN115624571A (zh) * 2022-12-21 2023-01-20 北京瑷格干细胞科技有限公司 人脂肪间充质干细胞在制备治疗硬皮病药物中的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018211486A1 (en) * 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
AU2018270396B2 (en) 2017-05-15 2025-03-20 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104130975A (zh) * 2013-05-03 2014-11-05 上海市东方医院 人源脂肪干细胞来源的神经元样细胞及其制备方法和应用
US20150216908A1 (en) * 2014-02-06 2015-08-06 Steminent Biotherapeutics Inc. Quadri-positive stromal cell (qpsc) population for superior cell protection and immunomodulation

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
PT1248643E (pt) 2000-01-20 2005-10-31 Yeda Res & Dev Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
NZ569331A (en) 2003-01-21 2010-08-27 Yeda Res & Dev COP 1 for treatment of inflammatory bowel diseases
US7429378B2 (en) 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
AU2005308396B2 (en) 2004-11-29 2011-06-09 Yeda Research And Development Co. Ltd. Induction of neurogenesis and stem cell therapy in combination with Copolymer 1
WO2006060779A2 (en) 2004-12-03 2006-06-08 Case Western Reserve University Novel methods, compositions and devices for inducing neovascularization
JP4654015B2 (ja) 2004-12-08 2011-03-16 京セラ株式会社 カメラ装置
US20070003528A1 (en) 2005-06-29 2007-01-04 Paul Consigny Intracoronary device and method of use thereof
NZ597304A (en) 2005-10-13 2013-06-28 Anthrogenesis Corp Immunomodulation using placental stem cells
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2008024996A2 (en) 2006-08-24 2008-02-28 Johnstone Brian H Production of neural protective and regenerative factors from stem cells and treatment of nervous system conditions therewith
WO2008057443A2 (en) 2006-11-03 2008-05-15 Multiple Sclerosis Research Center Of New York Bone marrow-derived mesenchymal stem cells as a source of neural progenitors
WO2011041240A1 (en) 2009-09-30 2011-04-07 The Brigham And Women's Hospital, Inc. Tissue transplant compositions and methods for use
US8703180B1 (en) 2007-10-23 2014-04-22 Abbott Cardiovascular Systems Inc. Multiple growth factor compositions, methods of fabrication, and methods of treatment
US8481253B2 (en) * 2008-03-19 2013-07-09 Cryo-Save Ag Cryopreservation of adipose tissue for the isolation of mesenchymal stem cells
US20090291061A1 (en) 2008-05-21 2009-11-26 Riordan Neil H Stem cell therapy for blood vessel degeneration
EP2620493B1 (en) 2008-05-28 2019-03-27 Ramot at Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
US20110129450A1 (en) 2008-08-01 2011-06-02 Orly Lazarov Method of promoting neurogenesis by modulating secretase activities
WO2010028051A2 (en) 2008-09-03 2010-03-11 Florida State University Research Foundation, Inc. Substituted heterocyclic mercaptosulfonamide metalloprotease inhibitors
CN102186968A (zh) 2008-10-17 2011-09-14 巴克斯特国际公司 从脂肪组织获得细胞群的方法
JP5515319B2 (ja) 2009-02-23 2014-06-11 富士レビオ株式会社 脂肪細胞への分化誘導培地及び方法
CA2767300C (en) 2009-07-09 2020-01-07 Cellerix Sa Methods and compositions for use in cellular therapies
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
JP5916622B2 (ja) 2010-01-04 2016-05-11 マピ ファーマ リミテッド グラチラマーまたはその薬理学的に許容される塩を含むデポーシステム
EP3351625A1 (en) 2010-02-18 2018-07-25 Osiris Therapeutics, Inc. Methods of manufacture of immunocompatible amniotic membrane products
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
US20130034524A1 (en) 2011-08-03 2013-02-07 Siamak Agha-Mohammadi Non-Enzymatic Method for Harvesting Adipose-Derived Stromal Cells and Adipose-Derived Stem Cells from Fat and Lipo-Aspirate
DK2744892T3 (en) 2011-09-23 2019-04-23 Cell Ideas Pty Ltd THERAPEUTICS USING FAT CELLS AND CELL SECRETIONS
CL2011002642A1 (es) 2011-10-24 2012-04-09 Univ Del Desarrollo Uso de una composicion formada por un glucocorticoide y una tiazolinediona que sirve para inducir la diferenciacion adipogenica en celulas madres.
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
EP2825638A4 (en) 2012-03-12 2015-11-25 Univ Singapore GENERATION OF BROWN FAT FABRIC FROM MESENCYCLES
WO2015120388A1 (en) * 2014-02-10 2015-08-13 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
CN109072189A (zh) 2016-02-12 2018-12-21 细胞治疗药物公司 脂肪组织衍生的间充质基质细胞条件培养基及其制备和使用方法
US12161688B2 (en) 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
AU2018270396B2 (en) 2017-05-15 2025-03-20 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104130975A (zh) * 2013-05-03 2014-11-05 上海市东方医院 人源脂肪干细胞来源的神经元样细胞及其制备方法和应用
US20150216908A1 (en) * 2014-02-06 2015-08-06 Steminent Biotherapeutics Inc. Quadri-positive stromal cell (qpsc) population for superior cell protection and immunomodulation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GABRIELA CONSTANTIN ET AL.: "Adipose-Derived Mesenchymal Stem Cells Ameliorate Chronic Experimental Autoimmune Encephalomyelitis" *
GABRIELA CONSTANTIN ET AL.: "Adipose-Derived Mesenchymal Stem Cells Ameliorate Chronic Experimental Autoimmune Encephalomyelitis", STEM CELLS, vol. 27, pages 2631 - 2635 *
WEI GONG 等: "Banking Human Umbilical Cord-Derived Mesenchymal Stromal Cells for Clinical Use", CELL TRANSPLANTATION, vol. 21, pages 209 *
梁星光: "干细胞移植在治疗神经退行性疾病方面的 临床应用", vol. 9, no. 4, pages 188 - 193 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115461447A (zh) * 2020-01-20 2022-12-09 干细胞医药有限公司 含有来自于脂肪源性干细胞的调制培养基的蛋白质浓缩物的美容组合物
US12514815B2 (en) 2020-01-20 2026-01-06 Stem Cell Medicine Ltd. Cosmetic compositions with protein concentrate from conditioned medium of adipose-derived stem cells
CN115624570A (zh) * 2022-12-21 2023-01-20 北京瑷格干细胞科技有限公司 人脂肪间充质干细胞在制备治疗结缔组织疾病药物中的应用
CN115624571A (zh) * 2022-12-21 2023-01-20 北京瑷格干细胞科技有限公司 人脂肪间充质干细胞在制备治疗硬皮病药物中的应用

Also Published As

Publication number Publication date
IL269893A (https=) 2019-11-28
CA3062123A1 (en) 2018-11-22
IL269893B2 (en) 2023-10-01
AU2018270396B2 (en) 2025-03-20
EP3624816A4 (en) 2021-02-24
JP2020519645A (ja) 2020-07-02
US20200188439A1 (en) 2020-06-18
AU2018270396A1 (en) 2020-01-02
WO2018211498A1 (en) 2018-11-22
US11510946B2 (en) 2022-11-29
IL269893B1 (en) 2023-06-01
EP3624816A1 (en) 2020-03-25

Similar Documents

Publication Publication Date Title
CN110573170A (zh) 使用脂肪来源的干细胞治疗多发性硬化症
US11041144B2 (en) Cell culture method
CN103340904B (zh) 治疗骨关节炎的组合物
JP2018531979A (ja) 間葉幹細胞由来のエクソソームおよびその使用
US20190201448A1 (en) Methods of treating or preventing neurological diseases
US10596199B2 (en) Methods of treating or preventing rheumatic disease
US20170106021A1 (en) Compositions enriched for hox11+ stem cells and methods of preparing the same
CN110885785B (zh) 一种分离培养间充质干细胞的方法
EP2931876B1 (en) Treatment of diseases of endothelial dysfunction and inflammation
CN105726571A (zh) 一种用于治疗椎间盘退行性变的脂肪间充质祖细胞复合物
WO2018017341A1 (en) Methods and compositions for rejuvenation
HK1228953A1 (en) Cell culture method
HK1228953B (en) Cell culture method
HK1210209B (en) Treatment of diseases of endothelial dysfunction and inflammation
HK1196948A (en) Methods of treating or preventing rheumatic disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191213

WD01 Invention patent application deemed withdrawn after publication